阿尔茨海默病:细胞和药理学方面
Gonzalo Emiliano Aranda-Abreu1, Fausto Rojas-Durán1, María Elena Hernández-Aguilar1
1Instituto de Investigaciones Cerebrales, Universidad Veracruzana, Xalapa 91192, Mexico.
Geriatrics (Basel, Switzerland)
|July 25, 2024
概括
目前阿尔茨海默病的治疗方法失败了,因为它们没有解决神经元损伤. 专注于神经元恢复疗法的新方法可以提高治疗效率和患者的生活质量.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 老年学是一门学科.
背景情况:
- 阿尔茨海默病 (AD) 已被认可超过一个世纪,但有效的治疗方法仍然难以捉摸.
- 目前在后期试验中的治疗分子往往由于缺乏在患病神经元中的有效性而失败.
- 阿尔茨海默氏症的神经病理包括关键的细胞损伤,包括血干扰和器官功能障碍.
研究的目的:
- 讨论神经元恢复治疗阿尔茨海默病的潜力.
- 探索如何针对神经元病理可以增强当前的治疗策略.
- 改善受阿尔茨海默病影响的个人的生活质量.
主要方法:
- 文献综述和对现有的阿尔茨海默病研究进行批判性分析.
- 讨论当前治疗方法的局限性.
- 一个新的治疗策略的概念化,专注于神经元修复.
主要成果:
- 目前的阿尔茨海默氏症治疗主要针对症状或病理特征,而不解决潜在的神经元损伤.
- 神经元损伤,包括膜破坏和器官功能障碍,显著损害了现有的候选药物的有效性.
- 转向恢复神经元功能的疗法,有望为更有效地管理阿尔茨海默病带来希望.
结论:
- 神经元恢复疗法代表了阿尔茨海默病治疗的有希望的范式转变.
- 通过解决神经退行症的细胞基础,这种疗法可以克服当前方法的局限性.
- 这种方法有可能显著改善患者的治疗结果和生活质量.
相关概念视频
Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
Alzheimer's Disease: Treatment
172
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
172
Parkinson's Disease: Overview
512
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
512
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
114
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
114
Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.2K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.2K
Dementia
110
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
110


